全球应用的前列腺癌预后风险分组比较与新诊断前列腺癌患者前列腺特异性膜抗原正电子发射断层扫描转移性疾病患病率
本研究回顾性分析2017至2022年间2630例新诊断前列腺癌患者,比较四种风险分类系统对PSMA-PET/CT初诊分期检出转移性疾病的预测价值。结果显示中间和高风险组转移患病率约12%至46%,NCCN和CPG进一步细分亚组后转移率差异明显(如NCCN有利中间5.8%至极高风险62%)。作者建议细分中间和高风险组,PSMA-PET/CT初诊分期应保留给不利中间风险或更高风险患者。
要点
- 2630例新诊断前列腺癌患者中,35%(931/2630)在PSMA-PET/CT上检出任何转移性疾病。
- NCCN风险组转移患病率:有利中间5.8%、不利中间13%、高风险22%、极高风险62%。
- CPG对应风险组转移患病率:6.9%、13%、21%、60%。
核心结论
- 本研究强调细致风险分层的重要性,鉴于转移性疾病患病率存在显著差异,建议进一步细分中间和高风险疾病。
- PSMA-PET/CT初诊分期应保留给不利中间风险或更高风险患者。
研究设计与样本
- 回顾性研究,纳入2017至2022年间新诊断前列腺癌并接受PSMA-PET/CT检查的患者。
- 共2630例男性患者,根据四种风险分类系统(欧洲泌尿外科学会、国家综合癌症网络NCCN、剑桥预后分组CPG和前列腺癌风险评估)进行风险分层。
主要发现
- 任何转移性疾病在35%(931/2630)的患者中观察到。
- 在分类为中间和高风险疾病的患者中,转移患病率范围约为12%至46%。
- 根据NCCN,有利中间、不利中间、高风险和极高风险前列腺癌的转移性疾病患病率分别为5.8%、13%、22%和62%。
- 关于CPG,相应风险组的这些数值分别为6.9%、13%、21%和60%。
临床怎么用
- 作者建议进一步细分中间和高风险疾病。
- 作者认为PSMA-PET/CT初诊分期应保留给不利中间风险或更高风险患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Various risk classification systems (RCSs) are used globally to stratify newly diagnosed patients with prostate cancer (PCa) into prognostic groups. OBJECTIVE: To compare the predictive value of different prognostic subgroups (low-, intermediate-, and high-risk disease) within the RCSs for detecting metastatic disease on prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) for primary staging, and to assess whether further subdivision of subgroups would be beneficial. DESIGN, SETTING, AND PARTICIPANTS: Patients with newly diagnosed PCa, in whom PSMA-PET/CT was performed between 2017 and 2022, were studied retrospectively. Patients were stratified into risk groups based on four RCSs: European Association of Urology, National Comprehensive Cancer Network (NCCN), Cambridge Prognostic Group (CPG), and Cancer of the Prostate Risk Assessment. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The prevalence of metastatic disease on PSMA-PET/CT was compared among the subgroups within the four RCSs. RESULTS AND LIMITATIONS: In total, 2630 men with newly diagnosed PCa were studied. Any metastatic disease was observed in 35% (931/2630) of patients. Among patients classified as having intermediate- and high-risk disease, the prevalence of metastases ranged from approximately 12% to 46%. Two RCSs further subdivided these groups. According to the NCCN, metastatic disease was observed in 5.8%, 13%, 22%, and 62% for favorable intermediate-, unfavorable intermediate-, high-, and very-high-risk PCa, respectively. Regarding the CPG, these values were 6.9%, 13%, 21%, and 60% for the corresponding risk groups. CONCLUSIONS: This study underlines the importance of nuanced risk stratification, recommending the further subdivision of intermediate- and high-risk disease given the notable variation in the prevalence of metastatic disease. PSMA-PET/CT for primary staging should be reserved for patients with unfavorable intermediate- or higher-risk disease. PATIENT SUMMARY: The use of various risk classification systems in patients with prostate cancer helps identify those at a higher risk of having metastatic disease on prostate-specific membrane antigen positron emission tomography/computed tomography for primary staging.
引用
- Luining WI, Boevé LMS, Hagens MJ, et al. A Comparison of Globally Applied Prognostic Risk Groups and the Prevalence of Metastatic Disease on Prostate-specific Membrane Antigen Positron Emission Tomography in Patients with Newly Diagnosed Prostate Cancer. Eur Urol Oncol. 2024. PMID: 38693019. doi:10.1016/j.euo.2024.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。